A Clinical Scenario: When "GLP-3" Comes Up in the Exam Room
A 54-year-old patient with an HbA1c of 8.2% and a body mass index of 33 sits across from an endocrinologist holding a printout from a research forum comparing "GLP-1 versus GLP-3 peptides." The patient wants to know which one is stronger. The honest answer requires separating two different things: an FDA-approved drug class with more than a decade of trial data, and a colloquial research-community label that does not correspond to an approved receptor system at all.
This scenario plays out often enough to warrant a direct comparison. GLP-1 receptor agonists — semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) chief among them — carry FDA-approved indications for type 2 diabetes and, in some formulations, chronic weight management. "GLP-3 peptide therapy," by contrast, is not a term tied to a validated endogenous hormone. It surfaces in peptide-research circles as shorthand for next-generation multi-receptor agonists, most notably retatrutide, a triple GIP/GLP-1/glucagon receptor agonist still moving through Phase 3 testing.
Clarifying that distinction upfront matters because clinical decisions built on a misunderstanding of trial status can lead a patient toward an unapproved or unlabeled use. The rest of this comparison lays out what the completed trial data actually shows for GLP-1 agonists, what is known and not known about the multi-agonist peptides sometimes mislabeled as "GLP-3," and where the evidence base for each currently stands.
What GLP-1 Receptor Agonists Are Actually Approved to Do
GLP-1 receptor agonists activate a single, well-characterized G-protein-coupled receptor expressed in pancreatic beta cells, the gastrointestinal tract, and specific brainstem and hypothalamic nuclei. Semaglutide received FDA approval for type 2 diabetes in 2017 (as Ozempic) and for chronic weight management in 2021 (as Wegovy). Tirzepatide, a dual GIP/GLP-1 receptor agonist, followed with approval for type 2 diabetes in 2022 (Mounjaro) and obesity in 2023 (Zepbound).
The evidence tier here is the strongest available in this comparison: multiple completed Phase 3 randomized controlled trials, published in peer-reviewed journals, with sample sizes in the thousands. SUSTAIN-7 (PMID 30293910) randomized 1,201 patients with type 2 diabetes to semaglutide 1 mg or dulaglutide 1.5 mg for 40 weeks, reporting HbA1c reductions of 1.5% versus 1.1%, respectively, and weight loss of 6.5 kg versus 3.0 kg.
These are not modest signals for a chronic metabolic disease trial. A 1.5% absolute HbA1c reduction, sustained, is clinically meaningful under ADA/EASD treatment-intensification frameworks, and it is why GLP-1 agonists have moved from third-line to earlier-line positioning in updated diabetes management guidance. The regulatory and evidentiary maturity of this class is the baseline against which any newer peptide — multi-agonist or otherwise — has to be measured.
Where the Term "GLP-3" Comes From — and Why It Isn't a Receptor Class
The proglucagon gene, expressed in pancreatic alpha cells, intestinal L-cells, and specific brainstem neurons, is cleaved into a defined set of peptides: glicentin, oxyntomodulin, GLP-1, and GLP-2. No GLP-3 peptide or receptor has been characterized in the peer-reviewed endocrinology literature. Searches of PubMed and ClinicalTrials.gov do not return a validated GLP-3 receptor system in human physiology.
What has happened, in practice, is a drift in informal usage. As multi-receptor peptides — dual GIP/GLP-1 agonists, triple GIP/GLP-1/glucagon agonists — moved through development, some research-community discussion began referring to "the next one after GLP-1" using ad hoc numbering. Retatrutide, the most clinically advanced compound in this category, is accurately described as a triple hormone receptor agonist, not as a "GLP-3" compound in any peer-reviewed sense.
This distinction is not pedantic. A clinician or researcher who treats "GLP-3" as an established, approved class risks misjudging both the maturity of the safety data and the regulatory status of anything marketed under that label. Research-grade peptides sold with "GLP-3" branding outside of regulated pharmaceutical channels fall into research-use-only labeling territory, with no FDA review of manufacturing, purity, or clinical safety — a materially different risk profile than an approved, prescribed GLP-1 agonist.
Mechanism: Single-Receptor vs. Multi-Receptor Incretin Pharmacology
Semaglutide binds the GLP-1 receptor with high affinity, driving glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite signaling through hypothalamic and brainstem GLP-1 receptor populations. Its half-life of approximately 165 hours supports once-weekly dosing, a pharmacokinetic property achieved through albumin binding via a fatty acid side chain.
Tirzepatide adds GIP receptor agonism to the same molecular scaffold. Preclinical characterization (Coskun et al., Mol Metab, 2018) showed balanced but distinct binding kinetics at each receptor, with the GIP-receptor component contributing additional insulinotropic and possibly adipose-tissue-modulating effects. The combined mechanism is the pharmacological explanation offered for tirzepatide's larger HbA1c and weight-loss effect sizes relative to GLP-1 monotherapy in head-to-head data.
Retatrutide extends this logic further by adding glucagon receptor agonism, theoretically increasing energy expenditure alongside appetite suppression — glucagon receptor activation is associated with increased hepatic glucose output in isolation, which is why pairing it with GLP-1/GIP agonism (which suppresses glucagon's glycemic effect while preserving its thermogenic signaling) is mechanistically significant rather than contradictory. Receptor-binding potency data (EC50 values) for retatrutide across all three receptors have been published in supporting pharmacology papers accompanying its Phase 2 program, though full comparative binding-affinity tables across all three compounds are not yet standardized in a single head-to-head assay.
Head-to-Head Data: SURPASS-2 and the GLP-1-vs-Dual-Agonist Comparison
The most direct comparative data available sits in SURPASS-2 (NCT03987919), a 40-week, randomized, open-label trial enrolling 1,879 patients with type 2 diabetes inadequately controlled on metformin (Frías et al., NEJM 2021, PMID 34170647). Patients received tirzepatide at 5 mg, 10 mg, or 15 mg, or semaglutide 1 mg.
Primary endpoint results: tirzepatide 15 mg produced a mean HbA1c reduction of 2.30%, versus 1.86% for semaglutide 1 mg — a between-group difference of 0.45 percentage points favoring the highest tirzepatide dose. Secondary endpoints told a similar story for body weight: tirzepatide 15 mg produced 11.2 kg of weight loss versus 5.7 kg for semaglutide, roughly double the effect size.
Attrition and tolerability were comparable across arms, which matters for interpreting the effect-size gap: the larger glycemic and weight response for tirzepatide was not purchased at the cost of materially higher discontinuation. In clinical decision-making terms, this trial supports tirzepatide as the higher-efficacy option among approved GLP-1-pathway agents for patients prioritizing larger HbA1c and weight reductions, while semaglutide remains a well-validated option with a longer accumulated safety record and broader long-term outcome data, including cardiovascular outcome trials (SUSTAIN-6, PMID 27633186).
Retatrutide and the "Beyond GLP-1" Triple-Agonist Data in Type 2 Diabetes
The Phase 2 trial most relevant to a GLP-1-vs-"next-generation-peptide" comparison is NCT04867785, a 36-week, randomized, placebo- and dulaglutide-controlled study of retatrutide in 281 patients with type 2 diabetes (Rosenstock et al., Lancet, 2023). Reported HbA1c reductions reached approximately 2.0% at the highest doses tested, with weight reductions substantially larger than those seen in the GLP-1-agonist trials described above.
The evidence tier here is materially different from SURPASS-2: this is a single mid-size Phase 2 trial, not a completed Phase 3 program, and the primary purpose was dose-finding and safety characterization rather than definitive efficacy confirmation. Longer-duration Phase 3 outcome data, including cardiovascular safety signals over multi-year follow-up, are not yet available for retatrutide in type 2 diabetes populations at the time of writing.
What is worth tracking: a companion obesity-focused Phase 2 trial (NCT04881760, Jastreboff et al., NEJM 2023) reported weight reductions exceeding 20% of body weight at the highest dose over 48 weeks — among the largest effect sizes reported for an incretin-pathway compound to date. Whether that magnitude of effect translates into proportionally larger glycemic benefit, and whether it holds up in a larger, longer Phase 3 population, is the open question the ongoing TRIUMPH program (NCT05929066 and related studies) is designed to answer.
Safety and Tolerability Signals Across the Comparison
Gastrointestinal adverse events are the dominant tolerability signal across this entire drug class, and they scale, roughly, with the number of receptors engaged and the speed of dose titration rather than with any single compound's inherent toxicity. In SURPASS-2, nausea rates ran approximately 17%-22% across tirzepatide doses versus around 18% for semaglutide — broadly comparable once titration schedules are matched.
In the retatrutide Phase 2 obesity trial, nausea reached roughly one-third of participants at the highest dose tested, with vomiting and diarrhea following a similar dose-dependent pattern. This is consistent with the mechanistic expectation that adding glucagon receptor agonism to GIP/GLP-1 activity does not eliminate the GI tolerability ceiling seen with dual agonism — it may extend it.
Class-wide contraindications for GLP-1-pathway agents include personal or family history of medullary thyroid carcinoma and MEN2 syndrome, based on rodent thyroid C-cell tumor signal (not yet confirmed in long-term human data at the same magnitude, but treated as a precautionary contraindication in FDA labeling). Pancreatitis, though rare in trial data, warrants attention to new-onset abdominal pain. Gallbladder-related events — cholelithiasis and cholecystitis — appear more frequently with faster or larger weight loss, a pattern observed across semaglutide, tirzepatide, and retatrutide trial safety tables alike.
Monitoring Requirements and Patient Selection
Baseline assessment for any GLP-1-pathway therapy typically includes HbA1c, renal function (given some renal clearance considerations and hydration status during GI side effects), and a personal/family thyroid cancer history screen. Ongoing monitoring during titration includes symptom review for GI tolerability, weight trajectory, and, for patients on concurrent insulin or sulfonylureas, closer glucose monitoring given additive hypoglycemia risk when insulin secretagogues are combined with an agent that itself increases insulin secretion.
Patient selection differentiates meaningfully between the approved GLP-1-pathway agents and anything discussed under the informal "GLP-3" umbrella. For semaglutide and tirzepatide, selection criteria are defined by FDA labeling: type 2 diabetes diagnosis, renal function within labeled parameters, and absence of the contraindications above. Dose titration schedules (semaglutide from 0.25 mg to maintenance; tirzepatide from 2.5 mg upward) exist specifically to manage GI tolerability during initiation.
For retatrutide and other investigational multi-agonist peptides, the only appropriate access pathway at this stage is enrollment in a registered clinical trial (searchable on ClinicalTrials.gov) or, eventually, an FDA-approved indication once Phase 3 data and regulatory review are complete. Sourcing an unapproved multi-agonist peptide outside a trial setting removes every monitoring safeguard described above — no standardized titration protocol, no verified purity, no adverse-event reporting infrastructure.
Access, Cost, and Regulatory Status
Semaglutide and tirzepatide sit in active, evolving payer and regulatory environments. Both carry FDA approval for type 2 diabetes, with diabetes-indication formulations generally receiving more consistent insurance coverage than the corresponding weight-management formulations (Wegovy, Zepbound), which face more variable prior-authorization requirements and, in many plans, exclusion from standard formularies absent a diabetes or specific comorbidity diagnosis.
Neither compound is DEA-scheduled; both are prescription-only under standard FDA drug approval pathways, dispensed through licensed pharmacies. Supply constraints have been a recurring feature of the market since 2022, with the FDA periodically updating drug shortage listings for both semaglutide and tirzepatide formulations, which has in turn fueled a compounding-pharmacy and gray-market peptide supplier landscape operating under research-use-only labeling — a distinct regulatory category from an FDA-approved prescription product.
Retatrutide has no FDA-approved indication and is not legally available as a prescribed product. It exists only within registered clinical trials or, outside that framework, within a research-chemical supplier landscape that operates under research-use-only labeling, explicitly not intended for human administration. Any peptide marketed to consumers as "GLP-3" for weight loss or diabetes management sits in this same unregulated category, regardless of what mechanistic claims accompany the marketing.
What the Evidence Actually Supports for Clinical Decision-Making
Stripped of terminology confusion, the comparison resolves into three tiers of evidence maturity. GLP-1 monotherapy (semaglutide) has the longest track record, including cardiovascular outcomes data. Dual GIP/GLP-1 agonism (tirzepatide) has completed Phase 3 head-to-head data showing a larger effect size on both HbA1c and weight, with a comparable tolerability profile in SURPASS-2. Triple agonism (retatrutide, informally and inaccurately sometimes called "GLP-3") has promising Phase 2 signal but lacks completed Phase 3 confirmation, long-term safety data, or an approved indication.
For a clinician working through treatment intensification with a patient today, the decision-relevant evidence points to tirzepatide or semaglutide as the compounds with regulatory approval and multi-year data behind them, not to a peptide still confined to trial enrollment. For a researcher or informed patient tracking the field, the retatrutide Phase 3 program (TRIUMPH) is the dataset to watch over the next 18-24 months, and it will determine whether the Phase 2 effect sizes hold up at scale.
The concrete next step for anyone weighing these options is straightforward: request the specific trial data — trial name, NCT number, primary endpoint, and completion status — before treating any compound as interchangeable with an approved therapy, and confirm current FDA labeling and clinical trial status directly through ClinicalTrials.gov and FDA.gov rather than through secondary summaries.
This article summarizes research and does not constitute medical advice. Consult a licensed clinician for diagnosis, treatment, or any decisions about medications or supplements.